These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17943658)

  • 1. The use of toxicokinetic data in preclinical safety assessment: a toxicologic pathologist perspective.
    Ploemen JP; Kramer H; Krajnc EI; Martin I
    Toxicol Pathol; 2007 Oct; 35(6):836-9. PubMed ID: 17943658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicokinetics in the National Toxicology Program.
    Goehl TJ
    NIDA Res Monogr; 1997; 173():273-304. PubMed ID: 9260193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of pharmacokinetics as an interpretive and predictive tool in chemical toxicology testing and risk assessment: a position paper on the appropriate use of pharmacokinetics in chemical toxicology.
    Frantz SW; Beatty PW; English JC; Hundley SG; Wilson AG
    Regul Toxicol Pharmacol; 1994 Jun; 19(3):317-37. PubMed ID: 8090955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of in vitro data in risk assessment.
    Bernauer U; Oberemm A; Madle S; Gundert-Remy U
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):176-81. PubMed ID: 15733212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of toxicokinetic data to dosage selection in toxicology studies.
    Morgan DG; Kelvin AS; Kinter LB; Fish CJ; Kerns WD; Rhodes G
    Toxicol Pathol; 1994; 22(2):112-23. PubMed ID: 7973359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetic and metabolic studies in the development of drugs].
    Vereczkey L
    Acta Pharm Hung; 1995 Jul; 65(4):105-11. PubMed ID: 7572191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Auditing drug metabolism protocols, data, and reports.
    Lucas G; Walls S
    Qual Assur; 1994 Jun; 3(2):193-7. PubMed ID: 7804636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the toxicologic pathologist in the biopharmaceutical industry.
    van Tongeren S; Fagerland JA; Conner MW; Diegel K; Donnelly K; Grubor B; Lopez-Martinez A; Bolliger AP; Sharma A; Tannehill-Gregg S; Turner PV; Wancket LM
    Int J Toxicol; 2011 Oct; 30(5):568-82. PubMed ID: 21878555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans.
    Dorne JL; Renwick AG
    Toxicol Sci; 2005 Jul; 86(1):20-6. PubMed ID: 15800035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of C(av) rather than AUC in safety assessment.
    Smith DA; Morgan P; Vogel WM; Walker DK
    Regul Toxicol Pharmacol; 2010 Jun; 57(1):70-3. PubMed ID: 20074607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the feasibility of using the DBS technique for metabolite radioprofiling.
    Wang L; Zeng Z; Emmons G
    Bioanalysis; 2010 Aug; 2(8):1365-71. PubMed ID: 21083337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of juvenile animal studies to determine the human effects and risks of environmental toxicants during postnatal developmental stages.
    Brent RL
    Birth Defects Res B Dev Reprod Toxicol; 2004 Oct; 71(5):303-20. PubMed ID: 15505806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The non-GLP toleration/dose range finding study: design and methodology used in an early toxicology screening program.
    Herlich JA; Taggart P; Proctor J; Stahle P; Colis R; Hall L; Pugsley MK
    Proc West Pharmacol Soc; 2009; 52():94-8. PubMed ID: 22128433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of gender differences for human health risk assessment and toxicology.
    Vahter M; Gochfeld M; Casati B; Thiruchelvam M; Falk-Filippson A; Kavlock R; Marafante E; Cory-Slechta D
    Environ Res; 2007 May; 104(1):70-84. PubMed ID: 17098226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Providing toxicokinetic support for reproductive toxicology studies in pharmaceutical development.
    Schwartz S
    Arch Toxicol; 2001 Sep; 75(7):381-7. PubMed ID: 11693177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicokinetics and physiologically based toxicokinetics in toxicology and risk assessment.
    Dixit R; Riviere J; Krishnan K; Andersen ME
    J Toxicol Environ Health B Crit Rev; 2003; 6(1):1-40. PubMed ID: 12587252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.
    Prueksaritanont T; Lin JH; Baillie TA
    Toxicol Appl Pharmacol; 2006 Dec; 217(2):143-52. PubMed ID: 17055014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant toxicokinetics: techniques for and interpretation of exposure data obtained during the conduct of toxicology studies.
    Dahlem AM; Allerheiligen SR; Vodicnik MJ
    Toxicol Pathol; 1995; 23(2):170-8. PubMed ID: 7569672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory forum opinion piece: differences between protein-based biologic products (biotherapeutics) and chemical entities (small molecules) of relevance to the toxicologic pathologist.
    Leach MW
    Toxicol Pathol; 2013 Jan; 41(1):128-36. PubMed ID: 22744226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.